Fiche centre
The Ottawa Hospital - General Campus
Ottawa — Canada
Essais liés9clinical trials
VilleOttawalocalisation
PaysCanadalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05538130
Essais cliniques associés
9| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| BMS-986368 | Myopathies | Phase 2 | NCT06782490 | MSS — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity | RECRUITING |
| Obinutuzumab | Cancer | Phase 3 | NCT06084936 | GLOBRYTE — A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | RECRUITING |
| BENCHMARK-SLE — A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants | Lupus | À vérifier | NCT07175285 | BENCHMARK-SLE — A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants | RECRUITING |
| PF-07799544 | Cancer | Phase 1 | NCT05538130 | A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT05269004 | OLERO — A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Interferon beta-1a | SEP | Phase 3 | NCT01412333 | A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis | COMPLETED |
| Ocrelizumab | SEP | Phase 3 | NCT01194570 | ORATORIO — A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis | COMPLETED |
| Fenebrutinib | SEP | Phase 3 | NCT04586023 | FENhance 2 — Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING |
| Fenebrutinib | SEP | Phase 3 | NCT04544449 | FENtrepid — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING |